MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

S. Jarius1,16*, K. Ruprecht2, J. P. Stellmann3,4, A. Huss5, I. Ayzenberg6, A. Willing3, C. Trebst7, M. Pawlitzki8, A. Abdelhak5, T. Grüter6, F. Leypoldt9, J. Haas1, I. Kleiter6,10, H. Tumani5,11, K. Fechner12, M. Reindl13, F. Paul2,14,15 and B. Wildemann1,16*

Abstract
Background: Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited data are available on the relevance of MOG-IgG testing in patients with chronic progressive demyelinating disease. It is unclear if patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) should routinely be tested for MOG-IgG.

Objective: To evaluate the frequency of MOG-IgG among patients classified as having PPMS or SPMS based on current diagnostic criteria.

Methods: For this purpose, we retrospectively tested serum samples of 200 patients with PPMS or SPMS for MOG-IgG using cell-based assays. In addition, we performed a review of the entire English language literature on MOG-IgG published between 2011 and 2017.

Results: None of 139 PPMS and 61 SPMS patients tested was positive for MOG-IgG. Based on a review of the literature, we identified 35 further MOG-IgG tests in patients with PPMS and 55 in patients with SPMS; the only reportedly positive sample was positive just at threshold level and was tested in a non-IgG-specific assay. In total, a single borderline positive result was observed among 290 tests.

Conclusion: Our data suggest that MOG-IgG is absent or extremely rare among patients with PPMS or SPMS. Routine screening of patients with typical PPMS/SPMS for MOG-IgG seems not to be justified.

Keywords: Myelin oligodendrocyte glycoprotein (MOG), Antibodies, Immunoglobulin G, MOG-IgG, Primary chronic progressive MS (PPMS), Secondary chronic progressive MS (SPMS), Neuromyelitis optica spectrum disorders (NMOSD)
Background
Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by cell-based assays have recently been implicated in the pathogenesis of central nervous system (CNS) demyelination [1]. Most adult MOG-IgG-positive patients present with optic neuritis (ON), myelitis or brainstem encephalitis, though supratentorial brain lesions and epileptic seizures may occur as well [2–9]. In addition, MOG-IgG has been demonstrated in (mostly paediatric) patients with acute disseminated encephalomyelitis. MOG-IgG-related encephalomyelitis (MOG-EM) is now considered by many experts a disease entity in its own right, pathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optic spectrum disorders [10]. So far, MOG-IgG has been almost exclusively reported in patients with monophasic or relapsing-remitting acute disease. However, as a major limitation, many previous studies had explicitly excluded patients with chronic progressive demyelination. It is therefore possible that MOG-IgG has so far been overlooked in patients with chronic progressive MS. To obtain more definite data on the role of MOG-IgG in chronic progressive CNS demyelination, we decided to test a large cohort of patients previously diagnosed with primary progressive MS (PPMS) or secondary progressive MS (SPMS) for MOG-IgG.

Methods
Serum samples from 200 patients with chronic progressive MS according to the 2010 McDonald criteria, comprising 139 with PPMS and 61 with SPMS, were retrospectively tested for MOG-IgG. Human embryonic kidney (HEK) 293 cells transfected with full-length human MOG were used as antigenic substrate in combination with control cells as previously described [4, 11]. Samples yielding both a titer of ≥ 1:10 in the fixed cell-based assay and a titer of ≥ 1:160 in the live cell-based assay were considered positive [4, 11]. The sex ratio was 1:1.2 (female to male) in the total cohort, 1:1.9 in the PPMS subgroup, and 1:0.36 in the SPMS subgroup. The median age at the time of testing was 48 years (range 18–77) in the total cohort, 51 (31–77) among patients with PPMS, and 47 (22–74) among patients with SPMS. The median expanded disability status scale (EDSS) score was 4.5 (range 1.5–9) in the total cohort, 4 (1.5–9) among patients with PPMS, and 6.5 (2–9) among patients with SPMS. The median disease duration at the time of blood sampling was 7.9 years (range 1–50.7) in the total cohort, 6 (range 1–36) in the PPMS subgroup, and 17 (range 1–50.7) in the SPMS subgroup. Data on treatment at the time of blood sampling were available from 188/200 (98%) patients; most patients (151/188 or 80.3%) were not treated with immunosuppressive drugs or steroids at the time of sampling. The study was approved by the institutional review boards of the participating centers. The patients gave written informed consent or were tested in an anonymised fashion as required by the institutional review board of the University of Heidelberg. Samples were stored at −80 °C prior to testing. Sixteen MOG-IgG-positive serum samples from previously reported patients with ON and/or myelitis were used as positive controls [2–5], including 13 samples that had previously yielded low-titer results in the live-cell assay (1:160–1:320). In addition, we performed a review of the entire literature on MOG-IgG published in English in journals indexed in the PubMed database of the US Library of Science at the US National Institutes of Health between 2011 and 2017.

Results
None of 200 patients with primary (N = 139) or secondary (N = 61) chronic progressive MS was positive for MOG-IgG. All positive controls were correctly detected. Based on a review of the English language literature, 35 additional tests for MOG-IgG in patients with PPMS and 55 in patients with SPMS were identified (Table 1). The only reportedly MOG-IgG-positive case we could identify in the literature—a patient previously diagnosed with SPMS—was positive just at threshold level when tested in a semiquantitative assay [11]. Considering the 200 patients tested in the present study and the 90 reported in the previous literature, MOG-IgG has been detected in 0/174 patients with PPMS and in 1/116 patients with SPMS, with the only reportedly positive sample having yielded a borderline result (Table 1). Moreover, the latter sample was positive in a semiquantitative assay employing a non-

Table 1 MOG-IgG in patients with PPMS and SPMS as found in the present study and as reported in the literature

|                | PPMS       | SPMS       |
|----------------|------------|------------|
| Jarius et al., present study | 139, none positive for MOG-IgG | 61, none positive for MOG-IgG |
| Jarius et al., J Neuroinflammation 2016 [4] | 5, none positive for MOG-IgG | 11, none positive for MOG-IgG |
| Martinez-Hernandez et al., JAMA Neurol 2015 [16] | 10, none positive for MOG-IgG | 9, none positive for MOG-IgG |
| Höftberger et al., Mult Scler 2015 [17] | 10, none positive for MOG-IgG | 10, none positive for MOG-IgG |
| Mader et al., J Neuroinflammation 2011 [11] | 8, none positive for MOG-IgG | 19, one borderline positive for MOG-IgG (1:160) |
| Ramanathan et al., Neurol Neuroimmunol Neuroinflamm 2014 [18] | 2, none positive for MOG-IgG | 6, none positive for MOG-IgG |
| Total          | 0/174      | 1/116 (borderline result) |
Discussion

Given the potential prognostic and therapeutic consequences of a chronic progressive disease course, addressing the question of whether MOG-IgG can be associated with chronic progressive demyelination is of high clinical relevance. Our data indicate that MOG-IgG is present only extremely rarely or not at all in adult patients diagnosed with PPMS or SPMS (one borderline result among 290 tests [0.3%]; see Table 1 for details).

The very low frequency of MOG-IgG among patients diagnosed with PPMS/SPMS on the one hand and the lack of standardized assays for MOG-IgG testing and the limited specificity of immunoassays in general on the other hand bears the significant risk of an unfavourable ratio of false-positive to true-positive results (a risk generally attached to screening of large cohorts for very rare markers [12, 13]). Based on the 0–0.3% positivity rate among PPMS/SPMS patients observed in this study, the number of false-positive results might even outnumber the number of true-positive results if all PPMS/SPMS patients were to be tested for MOG-IgG and assay specificity were to be less than 99.7–100%. Therefore, we advise against routine screening for MOG-IgG in patients with PPMS or SPMS. Instead, we recommend limiting MOG-IgG testing in patients with PPMS or SPMS to those with clinical and/or paraclinical findings considered suggestive of MOG-IgG-related encephalomyelitis, including, for example, predominant attacks of ON or myelitis, longitudinally extensive optic nerve or myelitis lesions, typical brain magnetic resonance imaging (e.g. normal supratentorial MRI; or no Dawson finger lesion, no juxtacortical U fibre lesion, no ovoid/round lesion adjacent to a lateral ventricle, and no lesion in the temporal lobe), or cerebrospinal fluid findings that are atypical for MS (e.g. negative oligoclonal bands, neuropheflic pleocytosis, or white cell count >50/µl) [2, 3, 14]. Finally, given that a progressive disease course seems to be rare in MOG-EM [3] and thus atypical, confirming a positive test result in patients with PPMS/SPMS using a second, methodologically independent assay or, if that is not possible, by testing of follow-up samples (ideally taken during acute relapse [3] and/or during treatment-free intervals) is advisable.

Finally, it should be taken into account that it can be difficult in clinical practice to distinguish between a secondary chronic progressive disease course and disability progression resulting from protracted attacks with incomplete remission or from mild attacks, some of which may be just below the patient’s threshold of attention. In case of doubt, MOG-IgG testing may therefore also be justified in selected patients with suspected chronic progressive disease, especially if the findings are otherwise suggestive of MOG-EM. However, confirmation of a positive result should be sought as outlined above.

We recognize that our study has potential limitations: First, all of our patients were adults. While to the best of our knowledge no paediatric patients with a progressive course and confirmed MOG-IgG-positive serostatus have yet been reported, further studies are certainly needed before any recommendations regarding MOG-IgG testing in children with chronic progressive CNS demyelinating disease can be made. Second, we report data from a European cohort; to formally rule out that genetic factors play a role, testing of other, e.g. Asian, populations seems advisable due to potential genetic differences. Third, treatment effects may influence antibody titers. However, the vast majority of patients analysed here were not treated with immunosuppressive drugs at the time of blood sampling, and MOG-IgG was also absent in all 151 patients not treated with immunosuppressants or steroids. Fourth, assessing disease activity in progressive MS according to current recommendations [15] requires monitoring of MRI activity over time, since relapses are typically rare or missing. As standardized MRI data were not available for the present cohort, we cannot formally exclude a potential effect of disease activity. However, it is likely that disease activity in our cohort was at least similar to that in the general PPMS/SPMS population, since unselected, consecutive patients were tested and since the sample size was high. Given that all patients were recruited at tertiary centers and that patients with inactive, stable disease are less likely to be seen at tertiary centers, disease activity may have been even higher than in the general PPMS/SPMS population. On the other hand, we count the multicenter design, which helped to lower the risk of selection bias, the additional literature review, and the very large number of patients tested among the strengths of this study.

Conclusion

In summary, our results argue against a major role of MOG-IgG in patients with primary or secondary progressive demyelination and may prove useful for future recommendations on clinical indications for MOG-IgG testing.

Abbreviations

AQP4: Aquaporin-4; CNS: Central nervous system; EM: Encephalomyelitis; IgG: Immunoglobulin G; MOG: Myelin oligodendrocyte glycoprotein; MS: Multiple sclerosis; PPMS: Primary progressive MS; SPMS: Secondary progressive MS

Acknowledgements

The authors are grateful to Mrs. Anja Eschlbeck, Mrs. Kathrin Schanda, and the Nikon Imaging Center at the University of Heidelberg for excellent technical support. The authors would like to thank the Dietmar Hopp Foundation and Merck Serono for supporting research on MOG-IgG. We acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding programme...
Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-Universität Heidelberg.

Funding
The work of S.W. was supported by research grants from the Dietmar Hopp Foundation, Germany; from Merck Serono, Germany; and from the German Federal Ministry of Education and Research (Competence Network Multiple Sclerosis); and by the Deutsche Forschungsgemeinschaft; the Baden-Württemberg Ministry of Science, Research and the Arts, and the Ruprecht-Karls-Universität Heidelberg (within the funding programme Open Access Publishing). FP is supported by Deutsche Forschungsgemeinschaft (DFG) Exc. 257. MR is supported by a research grants from the Austrian Federal Ministry of Science and Economy (grant BIG WG MS, Markus Reindl) and the Austrian Research promotion Agency (FFG, Bridge 1 project Nr. 853209 EDNA).

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available but are available from the corresponding author upon reasonable request.

Authors’ contributions
SJ and BW conceived and designed the study. SJ set up the database, collected data, analysed data, performed the statistical analysis, and wrote the manuscript. All authors collected and analysed the data. All authors were involved in revising the manuscript for intellectual content. All authors read and approved the final draft before submission.

Ethics approval and consent to participate
The study was approved by the institutional review boards of the participating centers. Patients gave written informed consent or were tested in an anonymised fashion as requested by the institutional review board of the University of Heidelberg.

Consent for publication
Not applicable.

Competing interests
BW has received research grants, speaking fees, and travel grants from Merck Serono, Biogen, Teva, Novartis, Sandofi Genzyme, Bayer Healthcare, the Klaus Tschira Stiftung, and the Dietmar Hopp Stiftung. JPS has received research grants and speaking fees from DFG, Biogen, and Genzyme not related to the present work. RR has received research grants from German Ministry of Education and Research (BMBF/KIKMMS, Competence Network Multiple Sclerosis), Novartis, Merck Serono, and the Charité Research Fund; honaroria for consultancy or speaking and travel reimbursement from Novartis, Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva Pharmaceuticals, and Guthy Jackson Charitable Foundation; all unrelated to the submitted work. MP received research grants, speaker honoraria, and travel/accommodation/meeting expenses from Novartis, and speaker honoraria from Genzyme, Biogen Idec., Merck Serono, and Roche. IU received honoraria for consultancy or speaking and travel reimbursement from Bayer Healthcare, Biogen, Chugai, Merck, Novartis, Roche, and Shire, and research support from Afectis, Biogen, Chugai and Diamed, all not related to the presented work. CT has received honoraria for consultation and expert testimony from Biogen Idec/GmbH, Genzyme GmbH and Novartis Pharmaceuticals; none of this interfered with the current report. K.F. is an employee of Euroimmun AG, Germany. FL is employed by a non-commercial academic institution (University Hospital Schleswig-Holstein) offering antibody testing. The University Hospital and Medical University of Innsbruck (Austria; M.R.) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). All authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. 2Department of Neurology, Charité – University Medicine Berlin, Berlin, Germany. 3Institut für Neuroimmunologie und Multiple Sklerose (INIMS), Zentrum für Molekulare Neurobiologie Hamburg, Universitätssklinikum Hamburg-Eppendorf, Hamburg, Germany. 4Klinik und Poliklinik für Neurologie, Universitätssklinikum Hamburg-Eppendorf, Hamburg, Germany. 5Department of Neurology, University of Ulm, Ulm, Germany. 6Department of Neurology, Ruhr University Bochum, Bochum, Germany. 7Department of Neurology, Hannover Medical School, Hanover, Germany. 8Department of Neurology, Otto von Guericke University Magdeburg, Magdeburg, Germany. 9Department of Neurology and Institute of Laboratory Medicine, University Hospital Schleswig-Holstein, Kiel, Germany. 10Marianne-Strauß-Klinik, Behandlungszentrum Kemptenhausen for Multiple Sclerosis Krane, Berg, Germany. 11Speciality Clinic of Neurology Dienerbronn, Schweidi, Germany. 12Institute of Experimental Immunology, affiliated to Euroimmun AG, Lübeck, Germany. 13Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. 14NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Free Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 15Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany. 16Otto Meyerhoff Center, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany.

Received: 19 January 2018 Accepted: 26 February 2018

Published online: 19 March 2018

References
1. Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol. 2017;30:295–301.
2. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarkokoli K, Borisov N, Hummert MW, Trebst C, Pache F, Winkelmann A, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement—frequency, presentation and outcome. J Neuroinflammation. 2016;13:281.
3. Jarius S, Ruprecht K, Kleiter I, Borisov N, Asgari N, Pitarkokoli K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.
4. Jarius S, Ruprecht K, Kleiter I, Borisov N, Asgari N, Pitarkokoli K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.
5. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.
6. Wildemann B, Jarius S, Schwarz A, Diem R, Viehow A, Hahnel S, Reindl M, Korpal-Kuhnke M. Failure of almentuzumab therapy to control MOG encephalomyelitis. Neurorolog. 2017;89:207–9.
7. Bouzar M, Daooudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J Neurol Sci. 2017;381:240–4.
8. Hamid SHM, Whitlam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhokal M, Woodhall M, Waters P, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurology. 2018;75:65–71.
9. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunool Neuroinflamm. 2017;4:e322.
10. Zamvil SS, Slavin AJ. Does MOG IgG-positive AQP4-seronegative optocipital inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunool Neuroinflamm. 2015;2:e56.
11. Kister I, Paul F, Schneider V, Schandl K, Rostasy K, Dujmovic J, Pfäffiger K, Lutterotti A, Jarius S, Di Paoli F, Kuenz B, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.
12. Kister I, Paul F. Pushing the boundaries of neuromyelitis optica: does antibody make the disease? Neurology. 2015;85:118–9.
13. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661–83.
14. Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, DeLuca C, Chandratte S, Leite M, Vincent A, Palace J. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140:617–27.
15. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1–5.
16. Martinez-Hernandez E, Sepulveda M, Rostasy K, Hoftberger R, Graus F, Harvey RJ, Saiz A, Dalmau J. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72:187–93.
17. Hoftberger R, Sepulveda M, Armanque T, Blanco Y, Rostasy K, Cobo Calvo A, Olascoaga J, Ramio-Torrenta L, Reindl M, Benito-Leon J, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21:866–74.
18. Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, Meetheb V, Kumaran RY, Pathmanandavel K, Simmaz N, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e40.